Ignite Creation Date:
2024-07-17 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06490614
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-08
First Post:
2024-06-29
Brief Title:
Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block
Sponsor:
Kasr El Aini Hospital
Organization:
Kasr El Aini Hospital
Study Overview
Official Title:
Comparative Study Between Dexmedetomidine and Nalbuphine as Analgesic Adjuvants to Bupivacaine in Superficial Cervical Block for Patients Undergoing Anterior Cervical Discectomy and Fusion ACDF Surgery A Double Blinded Randomized Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anterior cervical discectomy and fusion ACDF nowadays is considered a common procedurepostoperative pain can hinder recovery and prolong hospital stay The superficial cervical plexus block SCPB is a safe and simple technique that had been found to allow good pain relief in neck surgeries The main drawback of SCPB was short duration so adjuvants as dexmedetomidine and opioids has been used to increase analgesic duration and decrease the use of opioids
The current study will compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to bupivacaine in SCPB in anterior cervical fusion surgeries
The current study will compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to bupivacaine in SCPB in anterior cervical fusion surgeries
Detailed Description:
The aim of the current study is to evaluate whether the addition of Dexmedetomidine to bupivacaine is comparable to the addition of nalbuphine in superficial cervical plexus block in patients undergoing ACDF
thrity patients will be recruited Patients will be divided randomly into either group A in which patients will receive SCPB consisting of bupivacaine 025 dexmedetomidine 1 μgkg precedex 100mcgml and adrenaline 1200000 in a total volume of 10ml normal saline or Group B in which patients will receive SCPB consisting of bupivacaine 025 and 10 mg of Nalbuphine nalufin 20mgml and adrenaline 1200000 in a total volume of 10ml normal saline
thrity patients will be recruited Patients will be divided randomly into either group A in which patients will receive SCPB consisting of bupivacaine 025 dexmedetomidine 1 μgkg precedex 100mcgml and adrenaline 1200000 in a total volume of 10ml normal saline or Group B in which patients will receive SCPB consisting of bupivacaine 025 and 10 mg of Nalbuphine nalufin 20mgml and adrenaline 1200000 in a total volume of 10ml normal saline
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None